Publications by authors named "Petra J E Poels"
Introduction: Parkinson's disease (PD) is a complex and disabling disorder. Ultimately, 20% to 40% of patients are admitted to a nursing home, and neurologists often lose track of these patients. Care and treatment of these institutionalized patients have not been addressed comprehensively, but anecdotal reports suggest it is suboptimal.
View Article and Find Full Text PDFParkinson disease (PD) is common in long term care (LTC) facilities. The number of institutionalized patients with PD will rise sharply in the coming decades because of 2 concurrent phenomena: aging of the population leads to an increased PD prevalence and improved quality of care has led to a prolonged survival in advanced disease stages. Only a few studies have investigated the prevalence and clinical characteristics of patients with PD in LTC facilities.
View Article and Find Full Text PDFObjectives: To determine the prevalence of nonmotor symptoms (NMS) in nursing home (NH) residents with Parkinson's disease (PD) and to establish the association with quality of life.
Design: Cross-sectional.
Setting: Nursing homes in the southeast of the Netherlands.
Article Synopsis
- The study aimed to explore the characteristics, motor issues, and treatment approaches for nursing home residents with Parkinson's disease (PD) in the southeast Netherlands.
- Seventy-three residents were assessed, revealing that many experienced severe disabilities, with 49% wheelchair-bound and 44% in a troubling "off" motor state most of the time, while treatment primarily involved levodopa.
- Findings highlight significant motor impairments and inadequate treatment in nursing homes, suggesting a need for improved PD management through expert consultations or specialized care facilities.
Objective: To identify determinants for the discontinuation of non-ergoline dopamine agonist (DA) treatment in patients with Parkinson’s disease (PD) and to identify genetic determinants in genes encoding dopamine receptor (DR)D2 and DRD3 in a exploratory analysis.
Methods: Patients included were first-time users of the non-ergoline DA ropinirole or pramipexole who had been diagnosed with PD before 2005. Treatment discontinuation was defined as a gap of 180 days or more between two refills of the DA.
Objective: To compare characteristics and incidence of discontinuation of Parkinson's disease (PD) patients starting ropinirole or pramipexole in clinical practice with data from randomised controlled clinical trials (RCTs).
Methods: Included in the retrospective clinical-practice cohort were first-time users of ropinirole or pramipexole diagnosed with PD before 2005. Baseline characteristics and incidence of discontinuation were compared between the clinical-practice cohort and RCTs.